VYNE Therapeutics Inc. Common Stock (VYNE)

FairStock Score: 63/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Looking at VYNE Therapeutics, I see a clinical-stage biotech with 10 employees, not a proven operating business with a durable moat. In fiscal Q1 2026, revenue was $86,000, net income was -$3.6 million, and the margin was -4,168.60%. That is a research pipeline consuming capital, not a business producing owner earnings. The balance sheet gives only optical comfort: at the 2026-07-27 close, FairStock calculates a market cap of $21.4 million and a P/B of 0.75, while the P/E is -1.01. But trailing free cash flow was -$25.7 million, a FCF yield of -120.1%, so annual cash burn exceeds the entire equity value. FairStock's Piotroski score is 2/9 and its Altman Z-score is -30.13, both pointing to serious financial fragility. ROE is -63.16% and ROCE is -37.01%, confirming capital destruction. The supplied revenue growth of 54.76% and profit growth of 59.77% are positive but come off a near-zero base. Beta of 2.01 and a 52-week range of $0.32 to $46.95 show extreme volatility. The Lynch category is none because only 0 years of filed results exist, versus the 3 needed. VYN201 and VYN202 could create value if they succeed, but without earnings, stable cash flow, or a Graham-style margin of safety, the investment case rests on pipeline hope. Price alone is not value.

In plain English: VYNE Therapeutics is a tiny drug development company with 10 employees. It is testing treatments for chronic inflammatory conditions, but in fiscal Q1 2026 it had $86,000 of revenue and lost $3.6 million. The stock may look inexpensive compared with the value of its assets minus debts, but the business is unprofitable and burns cash, so the price is speculative rather than clearly cheap.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-07-27 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer